• News

Scout Bio Appoints Life Sciences Executive Aaron Schacht to Board of Directors

February 18, 2022

Brings experience in managing global innovation portfolios and business development to Scout Bio Executive leadership experience across both animal and human health PHILADELPHIA, February 18, 2022 – Scout Bio,…

  • News

Scout Bio to Present at Upcoming Animal Health Conferences

February 15, 2022

PHILADELPHIA, February 15, 2022 – Scout Bio, a biotechnology company developing therapeutic proteins and one-time AAV gene therapies for major chronic pet health conditions, today announced that it will…

  • News

Scout Bio Expands Gene Therapy Collaboration with the University of Pennsylvania Via Next-Generation Vector Technologies

December 7, 2021

Partnership agreement includes exclusive rights in animal health to novel viral vector capsid and expands additional option rights to novel capsids Next-generation novel adeno-associated viral (AAV) vector capsid promises…

  • News

Scout Bio Named Best New Start-Up for 2021

November 8, 2021

IHS Markit recognizes Scout Bio for pioneering therapies in companion animal medicine PHILADELPHIA, November 08, 2021 — Scout Bio, a biotechnology company focused on one-time AAV gene therapies for…

  • News

Scout Bio Initiates Multi-Center Clinical Study of Gene Therapy for Chronic Arthritis Pain In Cats

October 28, 2021

– First vectorized antibody gene therapy to be studied in pets – Strong initial in-species data support therapeutic profile of one-time gene therapy designed for long-term pain management –…

  • News

Scout Bio Closes $33 Million Series B2 Financing to Advance its Portfolio of Single Injection Gene Therapy Technology for the Treatment of Chronic Diseases in Pets

October 19, 2021

– Proceeds to support advancing single injection Adeno-Associated Viral (AAV) vector therapeutics targeting chronic companion animal diseases including diabetes, pain, and anemia associated with chronic kidney disease (CKD) – New…

  • News

Scout Bio to Present at Upcoming October Investor Conferences

October 4, 2021

PHILADELPHIA, Oct. 04, 2021 (GLOBE NEWSWIRE) — Scout Bio, a biotechnology company focused on revolutionizing pet medicine by delivering a pipeline of one-time AAV gene therapies for major chronic…

  • News

Scout Bio Successfully Completes Pilot Clinical Study of SB-001, A Single-Injection AAV Gene Therapy for the Treatment of Feline CKD-Associated Anemia

September 9, 2021

PHILADELPHIA, September 9, 2021 — Scout Bio today announced the successful completion of a CKD-associated anemia study in client owned cats treated with SB-001, an AAV expressing feline erythropoietin (fEPO).…

  • News

Scout Bio to Present at Stifel 2021 Virtual Jaws & Paws Conference

May 27, 2021

PHILADELPHIA, May 27, 2021 (GLOBE NEWSWIRE) — Scout Bio today announced that Mark Heffernan, Chief Executive Officer, will present at the upcoming Stifel 2021 Virtual Jaws & Paws Conference…

  • News

Scout Bio to Present at the BofA Securities 2021 Animal Health Summit

February 19, 2021

PHILADELPHIA, Feb. 18, 2021 (GLOBE NEWSWIRE) – Scout Bio, a biotechnology company revolutionizing pet medicine by delivering a pipeline of one-time gene therapies for major chronic pet health conditions,…

  • News

Scout Bio Advances Novel Gene Therapy for the Treatment of Feline Diabetes

October 28, 2020

Two pilot studies initiated to explore clinical applications for this convenient, one-time injectable treatment Positions Scout Bio as the first company to advance novel GLP-1 constructs for gene therapy…

  • News

Scout Bio Reports Statistically Significant Clinical Outcomes for Pilot Study of SB-001 for Treatment of CKD-Associated Anemia in Felines

September 30, 2020

SB-001, a gene therapy expressing feline erythropoietin (fEPO), demonstrates clinically relevant hematocrit improvements in end-stage anemia patients and improved quality of life scores PHILADELPHIA, Sept. 30, 2020 (GLOBE NEWSWIRE)…

  • News

Scout Bio to Present at Upcoming October Investor Conferences

September 28, 2020

PHILADELPHIA, September 28, 2020 – Scout Bio, a biotechnology company focused on revolutionizing pet medicine by delivering a pipeline of one-time AAV gene therapies for major chronic pet health conditions,…

  • News

Scout Bio Appoints Clinical Research Leader Dr. Anne Traas as Chief Development Officer

October 28, 2019

PHILADELPHIA, October 28, 2019 – Scout Bio, a biotechnology company focused on revolutionizing pet medicine by delivering a pipeline of one-time therapeutics for major chronic pet health conditions, today…

  • News

Scout Bio Announces $20 Million Financing to Advance Pipeline of One-time Therapies for Companion Animals

April 10, 2019

Financing to drive leadership in AAV vector-delivered one-time therapies for major chronic pet health conditions Company supported by leading life sciences investors and an R&D collaboration with the Gene…